Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

Oncotarget

Volumn 6, Issue 33, 2015, Pages 34221-34227

  Campesato, Luís Felipe ^a,b,c   Barroso Sousa, Romualdo ^b   Jimenez, Leandro ^a,b   Correa, Bruna R ^b   Sabbaga, Jorge ^b   Hoff, Paulo M ^b   Reis, Luiz F L ^b   Galante, Pedro Alexandre F ^b   Camargo, Anamaria A ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer gene panels; Immunotherapy; Mutational load; PD 1 blockade; Response prediction

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

ACCURACY; ARTICLE; CANCER GENE PANEL; CLINICAL PRACTICE; EXOME; GENE SEQUENCE; HUMAN; MELANOMA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; TUMOR GENE; WHOLE EXOME SEQUENCING; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; MUTATION; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MELANOMA; MUTATION; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; ROC CURVE;

EID: 84946615376     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5950     Document Type: Article

References (21)

1. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 2015; 33: 23-35.
2. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 2015; 23: 32-38.
3. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 2012; 366: 2455-2465.
4. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013; 369: 122-33.
5. Noguchi Y, Chen YT, Old LJ. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 3171-3175.
6. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995; 2: 45-59.
7. Dubey P, Hendrickson RC, Meredith SC, Siegel CT, Shabanowitz J, Skipper JC, Engelhard VH, Hunt DF, Schreiber H. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 1997; 185: 695-705.
8. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N. Engl. J. Med. 2014; 371: 2189-2199.
9. Rizvi N a., Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira a. L, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-. ). 2015; 348: 124-129.
10. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015; 372: 2509-20.
11. Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macrì E, Lanza G, Boiocchi M, Dolcetti R. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am. J. Pathol. 2001; 159: 297-304.
12. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumorinfiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001; 91: 2417-2422.
13. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 2015; 7: 283ra53-283ra53.
14. Cheng DT, Mitchell T, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, Brannon AR, O'Reilly C, Sadowska J, et al. MSK-IMPACT. A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J. Mol. Diagn. 2015; 17: 251-264.
15. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival. Cancer. 2010; 116: 1767-1775.
16. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 2012; 61: 1019-1031.
17. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 2014; 6: 238ra70.
18. Garon EB, Gandhi L, Rizvi N, Hui R, Balmanoukian a S, Patnaik a, Eder JP, Blumenshein GR, Aggarwal C, Soria J-C, Ahn M a, Gubens M a, Ramalingam SS, et al. Lba43Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation With Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) With Advanced Non-Small Cell Lung Carcinoma (Nsclc). Ann. Oncol. 2014; 25: 3475.
19. Taube JM, Klein AP, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014; 20: 5064-74.
20. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015; 373: 23-34.
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837-845.